SK pharmteco Focusing On BAU Amid BIO 'Buzz', BIOSECURE
Planned Act Already Prompting CDMO Shifts?
SK pharmteco CEO Joerg Ahlgrimm talks to Scrip about the "excitement" at BIO, potential CDMO shifts amid the US BIOSECURE Act, and the Korean CDMO's focus on business as usual as it seeks to diversify and grow.
